CAR T Cell Therapy: A Versatile Living Drug
International Journal of Molecular Sciences · 27.03.2023 · 24 (7) · 6300
DOI: 10.3390/ijms24076300 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.03.2023. Verfasst von Rodrigo C De Marco und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Engenharia da Universidade do Porto (FEUP), 4200-465 Porto, Portugal. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 112-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Finnish Cancer Foundation, Finnish Red Cross Blood Service, Sigrid Juselius Foundation.
Abstract (Originalsprache)
After seeing a dramatic increase in the development and use of immunotherapy and precision medicine over the past few decades, oncological care now embraces the start of the adoptive cell therapy (ACT) era. This impulse towards a new treatment paradigm has been led by chimeric antigen receptor (CAR) T cells, the only type of ACT medicinal product to be commercialized so far. Brought about by an ever-growing understanding of cellular engineering, CAR T cells are T lymphocytes genetically modified with an appropriate DNA construct, which endows them with expression of a CAR, a fusion protein between a ligand-specific recognition domain, often an antibody-like structure, and the activating signaling domain of the T cell receptor. Through this genetic enhancement, CAR T cells are engineered from a cancer patient’s own lymphocytes to better target and kill their cancer cells, and the current amassed data on clinical outcomes point to a stream of bright developments in the near future. Herein, from concept design and present-day manufacturing techniques to pressing hurdles and bright discoveries around the corner, we review and thoroughly describe the state of the art in CAR T cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculdade de Engenharia da Universidade do Porto (FEUP), 4200-465 Porto, Portugal.
- Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto, 4050-313 Porto, Portugal.
- Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.
ORCID-Profile: Rodrigo C De Marco, Päivi M Ojala
Förderung
- Finnish Cancer Foundation
- Finnish Red Cross Blood Service
- Sigrid Juselius Foundation
Zitieren
APA
De Marco, R. C., Monzo, H. J., & Ojala, P. M. (2023). CAR T Cell Therapy: A Versatile Living Drug. International Journal of Molecular Sciences, 24(7), 6300. https://doi.org/10.3390/ijms24076300
Vancouver
De Marco RC, Monzo HJ, Ojala PM. CAR T Cell Therapy: A Versatile Living Drug. International Journal of Molecular Sciences. 2023;24(7):6300. doi:10.3390/ijms24076300
BibTeX
@article{DeMarco2023,
author = {De Marco, Rodrigo C and Monzo, Hector J and Ojala, Päivi M},
title = {CAR T Cell Therapy: A Versatile Living Drug},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {7},
pages = {6300},
doi = {10.3390/ijms24076300}
}
EUVIMED